scholarly journals Syncope as the Initial Manifestation of a Late-Stage Renal Cell Carcinoma With Metastasis to the Brain

Cureus ◽  
2021 ◽  
Author(s):  
Grace W Ying ◽  
Hafiz Muhammad Jeelani ◽  
Michael J Chaney ◽  
Xuanzhen Piao ◽  
Nikita Jain ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Late Stage ◽  
Renal Cell ◽  
Initial Manifestation ◽  
The Brain

Pulmonary embolism—the initial manifestation of renal cell carcinoma in a young woman

2003 ◽  
Vol 10 (1) ◽  
pp. 43-45
Author(s):  
G. Gayer ◽  
S. Mini ◽  
D. Olchovsky ◽  
I. Leibovitch ◽  
S. Apter ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Pulmonary Embolism ◽  
Cell Carcinoma ◽  
Young Woman ◽  
Renal Cell ◽  
Initial Manifestation

scholarly journals Renal Cell Carcinoma Metastatic to the Scalp

Rare Tumors ◽  
2016 ◽  
Vol 8 (4) ◽  
pp. 139-141 ◽  
Author(s):  
Mounir Errami ◽  
Vitali Margulis ◽  
Sergio Huerta
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Natural History ◽  
Bone Metastases ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Metastatic Lesions ◽  
History Of ◽  
Rare Site ◽  
The Brain

Because of the asymptomatic natural history of renal cell carcinoma (RCC), by the time a diagnosis is made, metastatic disease is present in about one third of the cases. Thus, the overall survival of patients with RCC remains poor. Ultimately up to 50% of patients with RCC will develop metastases. Metastatic lesions from RCC are usually observed in the lungs, liver or bone. Metastases to the brain or the skin from RCC are rare. Here we present a patient diagnosed with RCC, found to have no evidence of metastases at the time of nephrectomy, who presented two years later with metastases to the scalp. We review the literature of patients with this rare site of metastasis and outline the overall prognosis of this lesion compared to other site of metastases from RCC.

scholarly journals Geographic Variation of Chronic Kidney Disease Prevalence: Correlation with the Incidence of Renal Cell Carcinoma or Urothelial Carcinoma?

2015 ◽  
Vol 2015 ◽  
pp. 1-7
Author(s):  
Yit-Sheung Yap ◽  
Kai-Wen Chuang ◽  
Chun-Ju Chiang ◽  
Hung-Yi Chuang ◽  
Sheng-Nan Lu
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Cell Carcinoma ◽  
Kidney Disease ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Late Stage ◽  
Renal Cell ◽  
Risk Groups ◽  
Incidence Rates ◽  
Geographic Variations

Background. The aim of this study is to evaluate whether geographic variations in the prevalence of late-stage chronic kidney disease (CKD) exist and are associated with incidence rates of renal cell carcinoma (RCC), upper tract urothelial carcinoma (UTUC), or lower tract urothelial carcinoma (LTUC).Methods. Prevalence rates of late-stage CKD for 366 townships (n>30) in Taiwan were calculated for 1,518,241 and 1,645,151 subjects aged 40 years or older in years 2010 and 2009, respectively. Late-stage CKD prevalence in year 2010 was used as a training set and its age-adjusted standardized morbidity rates (ASMR) were divided into three groups as defined <1.76%, 1.76% ≤ ASMR < 2.64%, and ≥2.64%, respectively. Year 2009, defined as the validation set, was used to validate the results.Results. The ASMR of late-stage CKD in years 2010 and 2009 were 1.76%, and 2.09%, respectively. Geographic variations were observed, with notably higher rates of disease in areas of the central, southwestern mountainside, and southeastern seaboard. There were no significant differences among different combined risk groups of RCC, UTUC, and LTUC incidence.Conclusion. The substantial geographic variations in the prevalence of late-stage CKD exist, but are not correlated with RCC, UTUC, or LTUC incidence.

Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control

2003 ◽  
Vol 98 (2) ◽  
pp. 342-349 ◽  
Author(s):  
Jason P. Sheehan ◽  
Ming-Hsi Sun ◽  
Douglas Kondziolka ◽  
John Flickinger ◽  
L. Dade Lunsford
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Cell Cancer ◽  
Local Tumor Control ◽  
Tumor Control ◽  
Content Type ◽  
Extracranial Disease ◽  
The Brain ◽  
Fine Print

Object. Renal cell carcinoma is a leading cause of death from cancer and its incidence is increasing. In many patients with renal cell cancer, metastasis to the brain develops at some time during the course of the disease. Corticosteroid therapy, radiotherapy, and resection have been the mainstays of treatment. Nonetheless, the median survival in patients with renal cell carcinoma metastasis is approximately 3 to 6 months. In this study the authors examined the efficacy of gamma knife surgery in treating renal cell carcinoma metastases to the brain and evaluated factors affecting long-term survival. Methods. The authors conducted a retrospective review of 69 patients undergoing stereotactic radiosurgery for a total of 146 renal cell cancer metastases. Clinical and radiographic data encompassing a 14-year treatment interval were collected. Multivariate analyses were used to determine significant prognostic factors influencing survival. The overall median length of survival was 15 months (range 1–65 months) from the diagnosis of brain metastasis. After radiosurgery, the median survival was 13 months in patients without and 5 months in those with active extracranial disease. In a multivariate analysis, factors significantly affecting the rate of survival included the following: 1) younger patient age (p = 0.0076); 2) preoperative Karnofsky Performance Scale score (p = 0.0012); 3) time from initial cancer diagnosis to brain metastasis diagnosis (p = 0.0017); 4) treatment dose to the tumor margin (p = 0.0252); 5) maximal treatment dose (p = 0.0127); and 6) treatment isodose (p = 0.0354). Prior tumor resection, chemotherapy, immunotherapy, or whole-brain radiation therapy did not correlate with extended survival. Postradiosurgical imaging of the brain demonstrated that 63% of the metastases had decreased, 33% remained stable, and 4% eventually increased in size. Two patients (2.9%) later underwent a craniotomy and resection for a tumor refractory to radiosurgery or a new symptomatic metastasis. Eighty-three percent of patients died of progression of extracranial disease. Conclusions. Stereotactic radiosurgery for treatment of renal cell carcinoma metastases to the brain provides effective local tumor control in approximately 96% of patients and a median length of survival of 15 months. Early detection of brain metastases, aggressive treatment of systemic disease, and a therapeutic strategy including radiosurgery can offer patients an extended survival.

scholarly journals Metastases of renal cell carcinoma to the larynx and thyroid: Two case reports on metastasis developing years after nephrectomy

2012 ◽  
Vol 6 (5) ◽  
Author(s):  
Lutfiye Demir ◽  
Cigdem Erten ◽  
Isil Somali ◽  
Alper Can ◽  
Ahmet Dirican ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Renal Cell ◽  
Case Reports ◽  
Neck Region ◽  
Metastatic Potential ◽  
Head And Neck Region ◽  
Neck Metastases ◽  
The Brain

Renal cell carcinoma (RCC) has a high metastatic potential due to its hematogen and vascular features. It metastasizes frequently to the lungs, the bones, the liver, the lymph nodes and the brain. Metastasis of RCC to the head and neck region is quite rare. In this case report, two RCC patients with head and neck metastases are presented: one occurring after 5 years and the other occurring 17 years after diagnosis.

scholarly journals Malabsorption Syndrome due to Intestinal Amyloidosis as Presentation of Renal Cell Carcinoma

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Filipe Bessa ◽  
Pedro Gaspar ◽  
Pedro Antunes Meireles ◽  
Maria Inês Parreira ◽  
Juliana Serrazina Pedro ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Rare Case ◽  
Early Recognition ◽  
Clinical Manifestations ◽  
Paraneoplastic Syndromes ◽  
Malabsorption Syndrome ◽  
Gastrointestinal Involvement ◽  
Initial Manifestation

Renal cell carcinoma accounts for approximately 3% of adult malignancies. Designated in the literature as “the great masquerader,” the great diversity of clinical manifestations is associated with the several paraneoplastic syndromes that potentially accompany it. Paraneoplastic amyloidosis is described in about 3–8% of cases, only exceptionally as an initial manifestation, with uncommon gastrointestinal involvement. A rare case of malabsorption by intestinal amyloidosis is presented as initial manifestation of renal cell carcinoma, emphasizing the need for early recognition of these paraneoplastic conditions.

Sign in / Sign up

Export Citation Format

Share Document